Alles anzeigenHallo Jeannette ,
Foglendes habe ich zu dem Stichwort "Lamm" gefunden, leider nur auf englisch.
Dr. Lamm ist ein Pionier in der Erforschung der BCG-Therapie, der sich auch dezidiert zu den veschiedenen Einnahme-Schemata äußert: wie oft und wie lange.So kann ich mich auch erinnern, daß Dr. Lamm mehrfach in den S3-Leitlinien Blasenkrebs in der Rubrik BCG-Therapie zitiert wurde. Vielleicht schaust Du dort einmal nach - alles auf deutsch.
Gruß, Aretha
Dr. Donald Lamm is Clinical Professor at the University of Arizona and Director of BCG Oncology in Phoenix, Arizona. Dr. Lamm holds a medical degree from the University of California, Los Angeles (UCLA). Following his internship at the University of Oregon in Portland, he spent two years working as Director of the Colville Indian Health Service Clinic. Subsequently, he returned to California for a residency in surgery at UCLA and a residency in urology at the University of California, San Diego (UCSD).
Dr. Lamm is a pioneer in the field of immunotherapy for bladder cancer. During his urology residency, Dr. Lamm developed an animal model for bladder cancer and found that bacillus Calmette-Guérin (BCG) inhibited tumor growth. While at the University of Texas Health Science Center in San Antonio, he was awarded a National Cancer Institute (NCI) contract that resulted in the first randomized clinical trial to demonstrate the superiority of BCG immunotherapy over transurethral resection of the bladder tumour (TURBT) alone. His subsequent research with the Southwest Oncology Group (SWOG) demonstrated that BCG was superior to Adriamycin. This work, with the help of an American Urological Association (AUA) petition signed by 1,500 urologists, led to Food and Drug Administration (FDA) approval of TheraCys BCG for the treatment of carcinoma in situ in 1990.
Dr. Lamm’s continued work with SWOG proved the superiority of BCG versus mitomycin C and resulted in FDA approval of Tice BCG for the prevention of recurrence of papillary tumors. The SWOG 8507 trial using his 3-week, 3-year maintenance schedule further demonstrated the superiority of maintenance BCG over 6-week induction therapy alone for reducing disease progression. Now in private genitourinary oncology practice, Dr. Lamm is working to develop improved immunotherapy and chemotherapy approaches for patients with bladder cancer.
Recent Contributions to PracticeUpdate:
- Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin
- Bacillus Calmette-Guérin Instillation Therapy for Nonmuscle Invasive Bladder Cancer
- Factors That Identify Risk Groups for Early Cystectomy in Bladder Cancer
- Optimizing Mitomycin C Therapy in Non–Muscle Invasive Bladder Canc
Liebe Aretha
Was zu lesen ist im Netz habe ich alles gelesen, nur fehlt mir einfach der Austausch mit Betroffenen die diese Therapie auch erleben.